• Tomivosertib Suppresses Spontaneous Activity in Human DRG Ne

  2026-06-26

  This study provides the first direct evidence that the MNK1/2 inhibitor Tomivosertib rapidly suppresses spontaneous activity in human dorsal root ganglion neurons from neuropathic pain patients. The findings highlight the MNK-eIF4E signaling pathway as a modifiable driver of neuronal hyperexcitability, opening new avenues for translational pain research.

• Liposomal Chlorin e6 PDT Triggers Pyroptosis and Tumor Immun

  2026-06-25

  The reference study demonstrates that liposomal Chlorin e6-mediated photodynamic therapy (PDT) eradicates breast cancer cells by inducing pyroptosis via mitochondrial oxidative damage and caspase-1 activation. This mechanism not only destroys tumor cells but also enhances anti-tumor immune responses, offering a promising approach for combinatorial cancer therapies.

• Next-Gen Firefly Luciferase mRNA: Stability, Immunity & LNP

  2026-06-25

  Explore how EZ Cap™ Firefly Luciferase mRNA (5-moUTP) redefines assay reproducibility by uniting advanced mRNA design with the latest lipid nanoparticle (LNP) delivery science. Delve into unique strategies for maximizing bioluminescent reporter sensitivity while minimizing innate immune activation.

• Non-Canonical Dlat-Trpv3 Pathway Drives Adipose Thermogenesi

  2026-06-24

  This study demonstrates that hyperforin activates a Dlat-Trpv3-AMPK signaling axis to promote adipose thermogenesis independently of canonical β3-adrenergic receptor mechanisms, offering a safer and more effective anti-obesity strategy. The findings establish a mechanistic basis for targeting adipose tissue via non-classical pathways, with translational relevance for obesity therapeutics.

• CD40–STING–TRAF2 Axis Regulates B Cell Activation in ESCC TL

  2026-06-23

  This study elucidates how competitive interactions between CD40 and STING for TRAF2 binding drive IRF4-mediated B cell activation within tertiary lymphoid structures (TLS) in esophageal squamous cell carcinoma (ESCC). The findings provide mechanistic insight into TLS-associated antitumor immunity and highlight new avenues for biomarker and immunotherapy development.

• Chlorpromazine in Advanced Hepatic Modeling: Beyond Dopamine

  2026-06-23

  Discover how chlorpromazine empowers antipsychotic and hepatic research by bridging dopaminergic signaling with advanced models of liver-nanoparticle interaction. This deep-dive explores practical assay implications, referencing new cellular insights.

• Reliable Gene Expression with HyperScript™ III RT SuperMix f

  2026-06-22

  This article provides a scenario-driven, evidence-based exploration of how HyperScript™ III RT SuperMix for qPCR (with gDNA wiper, SKU K1585) supports rigorous gene expression analysis in cell viability and cytotoxicity assays. By addressing real laboratory challenges—from genomic DNA contamination to high-GC transcript detection—this guide empowers biomedical researchers with actionable protocols and data-driven recommendations.

• lncRNA HNF4A-AS1 Loss Drives Sorafenib Resistance via Lipid

  2026-06-22

  This study reveals that decreased expression of lncRNA HNF4A-AS1 in hepatocellular carcinoma (HCC) cells facilitates resistance to sorafenib-induced ferroptosis by reprogramming lipid metabolism. The findings elucidate a mechanistic pathway involving m6A-mediated regulation of DECR1, highlighting HNF4A-AS1 as a potential target for overcoming drug resistance in HCC.

• Dual-Sensitive Nanocarriers and ROS Probes in Pancreatic Can

  2026-06-21

  The referenced ACS Nano study introduces a pH/ROS dual-sensitive nanocarrier that enhances chemotherapy penetration and efficacy by overcoming the dense extracellular matrix in orthotopic pancreatic cancer. This innovation leverages the tumor microenvironment’s unique features to achieve deeper drug delivery, with implications for the design of future nanomedicines and redox-based therapeutic strategies.

• RNA Pol II Inhibition Triggers Active Apoptosis via IIA Loss

  2026-06-20

  Harper et al. reveal that cell death following RNA Pol II inhibition is not a passive consequence of lost transcription, but rather an actively signaled apoptotic response initiated by loss of the hypophosphorylated RNA Pol IIA form. This mechanistic insight reframes how transcriptional inhibitors cause lethality and identifies new cellular checkpoints linking nuclear sensing to mitochondrial apoptosis.

• FH1 Small Molecule: Elevating Hepatocyte Maturation for Adva

  2026-06-19

  Discover how the FH1 small molecule enhances cultured hepatocyte function and advances iPS cell differentiation to mature hepatocyte-like cells. This in-depth analysis explores FH1’s mechanistic impact, protocol optimization, and its pivotal role in the future of liver cell therapy research.

• Optimizing AF Research: Dronedarone (Multaq) Lab Best Practi

  2026-06-19

  This article delivers an evidence-based, scenario-driven guide for biomedical researchers and lab technicians leveraging Dronedarone (Multaq) (SKU A3374) in atrial fibrillation research. Drawing on validated protocols, head-to-head comparisons, and expert troubleshooting, readers will discover how to maximize reproducibility, solubility, and data integrity using APExBIO's Dronedarone (Multaq).

• Cannabis Terpenes Relieve Neuropathic Pain via A2A Receptor

  2026-06-18

  Schwarz et al. demonstrate that select terpenes from Cannabis sativa exert robust antinociceptive effects in mouse models of chronic neuropathic pain via activation of adenosine A2A receptors, independent of canonical cannabinoid pathways. This mechanistic insight suggests new avenues for developing non-rewarding analgesics and highlights the complexity of Cannabis phytochemistry beyond CB1/CB2 targets.

• Erastin as a Ferroptosis Inducer: Workflows & Advanced Uses

  2026-06-18

  Erastin is a precision ferroptosis inducer empowering cancer biology and developmental research with selective, iron-dependent cell death. This article details optimized experimental workflows, troubleshooting strategies, and highlights the latest insights from spatial transcriptomics in developmental disease modeling.

• Partial BACE Inhibition Lowers Amyloid Beta Without Synaptic

  2026-06-17

  Satir et al. (2020) reveal that reducing amyloid beta (Aβ) production by up to 50% via partial β-secretase (BACE) inhibition does not impair synaptic transmission in cultured neurons. These findings refine therapeutic strategies for Alzheimer's disease by supporting moderate BACE inhibition as a safer approach, potentially mitigating adverse cognitive effects observed in prior clinical trials.

484 records 9/33 page Previous Next First page 上5页 678910 下5页 Last page